Cargando…
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Endocrine therapy is the mainstay of treatment of estrogen-receptor-positive (ER+) breast cancer with an overall survival benefit. However, some adaptive mechanisms in the tumor emerge leading to the development of a resistance to this therapy. A better characterization of this process is needed to...
Autores principales: | Augereau, Paule, Patsouris, Anne, Bourbouloux, Emmanuelle, Gourmelon, Carole, Abadie Lacourtoisie, Sophie, Berton Rigaud, Dominique, Soulié, Patrick, Frenel, Jean Sebastien, Campone, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424863/ https://www.ncbi.nlm.nih.gov/pubmed/28529550 http://dx.doi.org/10.1177/1758834017693195 |
Ejemplares similares
-
Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022) -
NY-ESO-1-Specific Circulating CD4(+) T Cells in Ovarian Cancer Patients Are Prevalently T(H)1 Type Cells Undetectable in the CD25(+)FOXP3(+)Treg Compartment
por: Redjimi, Nassima, et al.
Publicado: (2011) -
Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes
por: Billaud, Amandine, et al.
Publicado: (2021) -
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas
por: Loussouarn, D, et al.
Publicado: (2008) -
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)